Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial

Chetchotisakd, Ploenchan; Chierakul, Wirongrong; Chaowagul, Wipada; Anunnatsiri, Siriluck; Phimda, Kriangsak; Mootsikapun, Piroon; Chaisuksant, Seksan; Pilaikul, Jiraporn; Thinkhamrop, Bandit; Phiphitaporn, Sunchai; Susaengrat, Wattanachai; Toondee, Chalongchai; Wongrattanacheewin, Surasakdi; Wuthiekanun, Vanaporn; Chantratita, Narisara; Thaipadungpanit, Janjira; Day, Nicholas; Limmathurotsakul, Direk; J. Peacock, Sharon

doi:10.1016/s0140-6736(13)61951-0

Public

Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial

Published in The Lancet • Nov 24, 2013

Authors:

Ploenchan Chetchotisakd

Wirongrong Chierakul

Wipada Chaowagul

Abstract

BACKGROUND: Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, followed by oral drugs for at least 12 weeks. The standard oral regimen based on trial eviden...

Subject

Medicine

Melioidosis

Burkholderia pseudomallei

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!